Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Duerr

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
AIDS (London, England)|April 19, 2016
Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibitionPeter J Hayes, Josephine H Cox, Adam R Coleman, et al.
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
American Journal of Epidemiology|June 16, 2006
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative womenJill Koshiol, Jane Schroeder, Denise J Jamieson, et al.
Contemporary Clinical Trials|September 27, 2006
Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, MalawiAmy L Corneli, Ellen G Piwoz, Margaret E Bentley, et al.
Open Forum Infectious Diseases|May 25, 2022
Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance UseTrupti Gilada, Samuel R Schnittman, Edward White, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 29, 2020
Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical StudyJavier R Lama, Rachel A Bender Ignacio, Ricardo Alfaro, et al.
International Journal of Cancer|April 29, 2006
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatusJill E Koshiol, Jane C Schroeder, Denise J Jamieson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2007
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroadsHeather B Jaspan, Coleen K Cunningham, Tim J P Tucker, et al.
Vaccine|July 19, 2020
Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccineMarcel E Curlin, Jason Shao, Gabriela Diaz, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
AIDS (London, England)|April 19, 2016
Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibitionPeter J Hayes, Josephine H Cox, Adam R Coleman, et al.
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
American Journal of Epidemiology|June 16, 2006
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative womenJill Koshiol, Jane Schroeder, Denise J Jamieson, et al.
Contemporary Clinical Trials|September 27, 2006
Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, MalawiAmy L Corneli, Ellen G Piwoz, Margaret E Bentley, et al.
Open Forum Infectious Diseases|May 25, 2022
Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance UseTrupti Gilada, Samuel R Schnittman, Edward White, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 29, 2020
Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical StudyJavier R Lama, Rachel A Bender Ignacio, Ricardo Alfaro, et al.
International Journal of Cancer|April 29, 2006
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatusJill E Koshiol, Jane C Schroeder, Denise J Jamieson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2007
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroadsHeather B Jaspan, Coleen K Cunningham, Tim J P Tucker, et al.
Vaccine|July 19, 2020
Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccineMarcel E Curlin, Jason Shao, Gabriela Diaz, et al.
Pageof 14